Navigation Links
ZIOPHARM Presents Data on Orally Active ZIO-201 at AACR

LOS ANGELES--(BUSINESS WIRE)--Apr 16, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today the presentation of preclinical data for an orally active form of ZIO-201 (isophosphoramide mustard - IPM) at the American Association of Cancer Research meeting being held in Los Angeles. Data presented demonstrated oral availability of ZIO-201 and activity in a variety of cancer models, including those with ifosfamide (IFOS) and cyclophosphamide resistant tumors. An oral form of IPM, the primary therapeutic component of IFOS, without the toxic metabolites of IFOS, could extend the therapeutic utility of ZIO-201 well beyond that of IFOS.

"Ifosfamide has been tested as an oral drug but it is problematic at effective doses because of toxicity. Both an oral and IV form of ZIO-201 may offer clinicians an effective alternative to IFOS without the debilitating side effects associated with the other metabolites of IFOS," commented Barbara Wallner, Ph.D., Chief Technical Officer at ZIOPHARM.

About ZIO-201

ZIO-201, the active moiety of IFOS, is a bi-functional alkylator that causes irreparable inter-strand DNA cross-linking resulting in cell death. ZIO-201 is equal to or more active than IFOS in diverse cancer models. Unlike IFOS, which is a pro-drug, ZIO-201 is directly active against cancer cells. Also, unlike IFOS, ZIO-201 is not metabolized to acrolein or chloroacetaldehyde which cause bladder or central nervous system toxicities. ZIO-201 continues in a phase I trial in diverse cancers exploring maximum tolerated dose at alternate schedules. A phase II trial in advanced sarcoma continues to enroll patients. Trials in lymphoma and pediatric cancers are in the advanced planning stage. An oral form of ZIO-201 is in advanced preclinical development.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse , risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.

ZIOP-G

Contact

ZIOPHARM Oncology, Inc.
Investors
Suzanne McKenna, 646-214-0703
smckenna@ziopharm.com
or
Media
Tina Posterli, 917-322-2565
tposterli@r xir.com


'"/>




Related medicine technology :

1. ZIOPHARM to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR
3. ZIOPHARM Presents Unique Mechanism Data for Indibulin at AACR
4. ZIOPHARM Presents ZIO-201 Lymphoma Data at ISH
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
8. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
9. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... , June 19, 2017  Hill-Rom Holdings, Inc. (NYSE: ... call and webcast on Friday, July 28, 2017, beginning at ... Call Audio Only Dial-in information: To participate in the conference ... dial into the call at least 10 minutes prior to ... is 34090339.  Webcast: ...
(Date:6/16/2017)... , June 16, 2017  Exactly 50 years ago today, ... what later became known as the San Francisco "Summer of ... is unveiling two radical innovations in strategic market research portals ... announcement marks the beginning of Northern Light,s "Summer of Love ... ...
(Date:6/14/2017)... -- In 2016, Embodied Labs took top prize ... came away with $25,000 in seed-fund investment. Embodied Labs ... "entering the life of another" and by the Journal ... medical professionals in an entirely new dimension." Building upon ... for the Department of Education,s EdSimChallenge, where they received ...
Breaking Medicine Technology:
(Date:6/24/2017)... (PRWEB) , ... June 24, 2017 , ... ... in Erie, PA at the Sheraton Erie Bayfront and Erie Convention Center on ... based medicine experience, exhibits, a student quiz bowl, award and scholarship presentations, and ...
(Date:6/23/2017)... ... 2017 , ... "The Better Care Reconciliation Act (BCRA) falls ... people with all chronic conditions, including mental illnesses, while increasing the cost of ... Care Act (ACA) requirement that insurers cover pre-existing conditions, it does not require ...
(Date:6/23/2017)... NY (PRWEB) , ... June 23, 2017 , ... ... certified plastic surgeon practicing in Newburgh, New York, has recently begun offering three ... Committed to offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is ...
(Date:6/23/2017)... ... 23, 2017 , ... Ensuring meat products have reached the ... importance of correctly using a meat thermometer. The videos feature University of California ... consumer food safety habits. Dr. Bruhn explains the variety of meat thermometers available ...
(Date:6/23/2017)... ... 2017 , ... Ross Insurance Agency ( http://www.rossinsuranceagency.com ) saves ... Agency’s (FEMA) recent update of flood zones, more people than ever are in ... enacted to reflect the actual risk in flood zone areas during a time ...
Breaking Medicine News(10 mins):